Sfoglia per Autore
MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC)
2015 Catenacci, Daniel Virgil Thomas; Tang, Rui; Oliner, Kelly Smith; Ang, Agnes; Loberg, Robert D.; O'Day, Emily; Xu, Peng; Henderson, Les; Ruzzo, Annamaria; Graziano, Francesco
Pharmacogenetic profiling for toxicity of oxaliplatin and fluoropyrimidines. Final report from an ancillary protocol to the TOSCA (Three Or Six Colon Adjuvant) trial
2014 F., Graziano; Ruzzo, Annamaria; F., Galli; E., Giacomini; Ic, Floriani; E., Rulli; S., Lonardi; M., Ronzoni; B., Massidda; V., Zagonel; N., Pella; C., Mucciarini; R., Labianca; E., Veltri; P., Sozzi; S., Barni; V., Ricci; A., Sobrero; Magnani, Mauro
Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy
2014 F., Graziano; V., Catalano; P., Lorenzini; Giacomini, Elisa; D., Sarti; G., Fiorentini; M., De Nictolis; Magnani, Mauro; Ruzzo, Annamaria
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients
2014 Ruzzo, Annamaria; Francesco, Graziano; Fabio, Galli; Giacomini, Elisa; Irene, Floriani; Francesca, Galli; Eliana, Rulli; Sara, Lonardi; Monica, Ronzoni; Bruno, Massidda; Vittorina, Zagonel; Nicoletta, Pella; Claudia, Mucciarini; Roberto, Labianca; Maria Teresa, Ionta; Enzo, Veltri; Pietro, Sozzi; Sandro, Barni; Vincenzo, Ricci; Luisa, Foltran; Mario, Nicolini; Edoardo, Biondi; Annalisa, Bramati; Daniele, Turci; Silvia, Lazzarelli; Claudio, Verusio; Francesca, Bergamo; Alberto, Sobrero; Luciano, Frontini; Magnani, Mauro
Genetic modulation of the Interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy
2014 Ruzzo, Annamaria; V., Catalano; E., Canestrari; Giacomini, Elisa; D., Santini; G., Tonini; B., Vincenzi; G., Fiorentini; Magnani, Mauro; F., Graziano
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients
2014 F., Loupakis; C., Antoniotti; C., Cremolini; W., Zhang; D., Yang; T., Wakatsuki; P., Bohanes; M., Schirripa; L., Salvatore; G., Masi; V., Ricci; F., Graziano; Ruzzo, Annamaria; L., Benhaim; F., Marmorino; Y., Ning; R., El Khoueiry; A., Falcone; H. J., Lenz
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
2014 F. V., Negri; A., Musolino; N., Naldi; B., Bortesi; G., Missale; D., Laccabue; A., Zerbini A; R., Camisa; N., Chernyschova; G., Bisagni; F., Loupakis; Ruzzo, Annamaria; T. M., Neri; A., Ardizzoni
Evaluation of Period 2 gene (PER-2) biologic profile in advanced colorectal cancer (ACC) patients treated with chronomodulated chemotherapy
2013 A., Torsello; E., Melucci; Ruzzo, Annamaria; I., Sperduti; E., Giacomini; M., Zeuli; A., Gelibter; V., Ferraresi; M. G., Diodoro; Magnani, Mauro; M., Mottolese; F., Cognetti; C., Garufi
PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL
2013 Ruzzo, Annamaria; F., Galli; E., Giacomini; I., Floriani; E., Rulli; F., Galli; S., Lonardi; B., Massidda; N., Pella; C., Mucciarini; R., Labianca; E., Veltri; P., Sozzi; S., Barni; E., Pasquini; A., Sobrero; L., Frontini; Magnani, Mauro; F., Graziano
Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts)
2013 Melucci, E; Torsello, A; Ruzzo, Annamaria; Sperduti, I; Giacomini, E; Zeuli, M; Gelibter, A; Ferraresi, V; Diodoro, Mg; Magnani, Mauro; Mottolese, M; Cognetti, F; Garufi, C.
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
2013 F., Loupakis; C., Cremolini; D., Yang; L., Salvatore; W., Zhang; T., Wakatsuki; P., Bohanes; M., Schirripa; L., Benhaim; S., Lonardi; C., Antoniotti; G., Aprile; F., Graziano; Ruzzo, Annamaria; S., Lucchesi; M., Ronzoni; F., De Vita; G., Tonini; A., Falcone; H. J., Lenz
The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome
2013 Isidori, A; Ruzzo, Annamaria; Loscocco, F; Voso, Mt; Graziano, F; Barulli, S; Canestrari, E; Volpe, A; Magro, D; Piccaluga, Pp; Fuligni, F; Paolini, S; Ricciardi, Teresa; Picardi, P; Giacomini, Elisa; Rocchi, MARCO BRUNO LUIGI; Magnani, Mauro; Visani, G.
Prospective Study of EGFR Intron 1 CA tandem repeats as predict factor benefit from cetuximab and irinotecan
2012 Antoniotti, C; Loupakis, F; Cremolini, C; Zhang, W; Yang, Dy; Wakatsuki, T; Schirripa, M; Salvatore, L; Ricci, V; Graziano, F; Masi, G; Ruzzo, Annamaria; Labonte, Mj; Ning, Y; El Khoueiry, R; Falcone, A; Lenz, Hj
Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial
2012 Ruzzo, Annamaria; Galli, F; Floriani, I; Rulli, E; Zagonel, V; Lonardi, S; Ronzoni, M; Massidda, B; Pella, N; Mucciarini, C; Labianca, R; Ziranu, P; Veltri, E; Sozzi, P; Barni, S; Ricci, V; Foltran, L; Pasquini, E; Nuzzo, A; Bramati, A; Turci, D; Lazzarelli, S; Verusio, C; Bergamo, F; Giacomini, E; Sobrero, A; Frontini, L; Magnani, Mauro; Graziano, F.
High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease
2012 Ruzzo, Annamaria; Graziano, F; Vincenzi, B; Canestrari, E; Perrone, G; Galluccio, N; Catalano, V; Loupakis, F; Rabitti, C; Santini, D; Tonini, G; Fiorentini, G; Rossi, D; Falcone, A; Magnani, Mauro
Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV)
2012 Cremolini, C.; Loupakis, F.; Yang, Dy; Salvatore, L.; Zhang, W.; Wakatsuki, T.; Schirripa, M.; Lonardi, S.; Antoniotti, C.; Aprile, G.; Masi, G.; Graziano, F.; Ruzzo, Annamaria; Lucchesi, S.; Ronzoni, M.; Maus, Mkh; Bocci, G.; Tonini, G.; Falcone, A.; Lenz, Hj
PROSPECTIVE EVALUATION OF CANDIDATE SNPS OF VEGF/VEGFR PATHWAY IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV)
2012 Cremolini, C; Loupakis, F; Yang, Dy; Salvatore, L; Zhang, W; Wakatsuky, T; Schirripa, M; Antoniotti, C; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Maus, M; Bocci, G; Falcone, A; Lenz, Hj; Lonardi, S
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
2012 Vincenzi, B; Santini, D; Perrone, G; Graziano, F; Loupakis, F; Schiavon, G; Frezza, Am; Ruzzo, Annamaria; Rizzo, S; Crucitti, P; Galluzzo, S; Zoccoli, A; Rabitti, C; Muda, Ao; Russo, A; Falcone, A; Tonini, G.
Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR
2011 Canestrari, E; Ruzzo, Annamaria; Vincenzi, B; Galluccio, N; Perrone, G; Andreoni, Francesca; Lorenzini, P; Rulli, E; D'Emidio, S; Catalano, V; Loupakis, F; Bisonni, R; Floriani, I; De Nictolis, M; Santini, D; Salvatore, L; Tonini, G; Falcone, A; Magnani, Mauro; Graziano, F.
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
2011 Loupakis, F; Ruzzo, Annamaria; Salvatore, L; Cremolini, C; Masi, G; Frumento, P; Schirripa, M; Catalano, V; Galluccio, N; Canestrari, E; Vincenzi, B; Santini, D; Bencardino, K; Ricci, V; Manzoni, M; Danova, M; Tonini, G; Magnani, Mauro; Falcone, A; Graziano, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC) | 1-gen-2015 | Catenacci, Daniel Virgil Thomas; Tang, Rui; Oliner, Kelly Smith; Ang, Agnes; Loberg, Robert D.; O'Day, Emily; Xu, Peng; Henderson, Les; Ruzzo, Annamaria; Graziano, Francesco | |
| Pharmacogenetic profiling for toxicity of oxaliplatin and fluoropyrimidines. Final report from an ancillary protocol to the TOSCA (Three Or Six Colon Adjuvant) trial | 1-gen-2014 | F., Graziano; Ruzzo, Annamaria; F., Galli; E., Giacomini; Ic, Floriani; E., Rulli; S., Lonardi; M., Ronzoni; B., Massidda; V., Zagonel; N., Pella; C., Mucciarini; R., Labianca; E., Veltri; P., Sozzi; S., Barni; V., Ricci; A., Sobrero; Magnani, Mauro | |
| Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy | 1-gen-2014 | F., Graziano; V., Catalano; P., Lorenzini; Giacomini, Elisa; D., Sarti; G., Fiorentini; M., De Nictolis; Magnani, Mauro; Ruzzo, Annamaria | |
| Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients | 1-gen-2014 | Ruzzo, Annamaria; Francesco, Graziano; Fabio, Galli; Giacomini, Elisa; Irene, Floriani; Francesca, Galli; Eliana, Rulli; Sara, Lonardi; Monica, Ronzoni; Bruno, Massidda; Vittorina, Zagonel; Nicoletta, Pella; Claudia, Mucciarini; Roberto, Labianca; Maria Teresa, Ionta; Enzo, Veltri; Pietro, Sozzi; Sandro, Barni; Vincenzo, Ricci; Luisa, Foltran; Mario, Nicolini; Edoardo, Biondi; Annalisa, Bramati; Daniele, Turci; Silvia, Lazzarelli; Claudio, Verusio; Francesca, Bergamo; Alberto, Sobrero; Luciano, Frontini; Magnani, Mauro | |
| Genetic modulation of the Interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy | 1-gen-2014 | Ruzzo, Annamaria; V., Catalano; E., Canestrari; Giacomini, Elisa; D., Santini; G., Tonini; B., Vincenzi; G., Fiorentini; Magnani, Mauro; F., Graziano | |
| Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients | 1-gen-2014 | F., Loupakis; C., Antoniotti; C., Cremolini; W., Zhang; D., Yang; T., Wakatsuki; P., Bohanes; M., Schirripa; L., Salvatore; G., Masi; V., Ricci; F., Graziano; Ruzzo, Annamaria; L., Benhaim; F., Marmorino; Y., Ning; R., El Khoueiry; A., Falcone; H. J., Lenz | |
| Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy | 1-gen-2014 | F. V., Negri; A., Musolino; N., Naldi; B., Bortesi; G., Missale; D., Laccabue; A., Zerbini A; R., Camisa; N., Chernyschova; G., Bisagni; F., Loupakis; Ruzzo, Annamaria; T. M., Neri; A., Ardizzoni | |
| Evaluation of Period 2 gene (PER-2) biologic profile in advanced colorectal cancer (ACC) patients treated with chronomodulated chemotherapy | 1-gen-2013 | A., Torsello; E., Melucci; Ruzzo, Annamaria; I., Sperduti; E., Giacomini; M., Zeuli; A., Gelibter; V., Ferraresi; M. G., Diodoro; Magnani, Mauro; M., Mottolese; F., Cognetti; C., Garufi | |
| PHARMACOGENETIC PROFILING FOR TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINES. FINAL REPORT FROM AN ANCILLARY PROTOCOL TO THE TOSCA TRIAL | 1-gen-2013 | Ruzzo, Annamaria; F., Galli; E., Giacomini; I., Floriani; E., Rulli; F., Galli; S., Lonardi; B., Massidda; N., Pella; C., Mucciarini; R., Labianca; E., Veltri; P., Sozzi; S., Barni; E., Pasquini; A., Sobrero; L., Frontini; Magnani, Mauro; F., Graziano | |
| Period 2 (PER-2) biologic profile in advanced colorectal cancer (ACC) patients (pts) | 1-gen-2013 | Melucci, E; Torsello, A; Ruzzo, Annamaria; Sperduti, I; Giacomini, E; Zeuli, M; Gelibter, A; Ferraresi, V; Diodoro, Mg; Magnani, Mauro; Mottolese, M; Cognetti, F; Garufi, C. | |
| Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. | 1-gen-2013 | F., Loupakis; C., Cremolini; D., Yang; L., Salvatore; W., Zhang; T., Wakatsuki; P., Bohanes; M., Schirripa; L., Benhaim; S., Lonardi; C., Antoniotti; G., Aprile; F., Graziano; Ruzzo, Annamaria; S., Lucchesi; M., Ronzoni; F., De Vita; G., Tonini; A., Falcone; H. J., Lenz | |
| The Mutational Status Of Genes Involved In DNA Repair and Folate Pathway Predicts Overall Survival Of Patients With Low-Risk, Untreated Myelodysplastic Syndrome | 1-gen-2013 | Isidori, A; Ruzzo, Annamaria; Loscocco, F; Voso, Mt; Graziano, F; Barulli, S; Canestrari, E; Volpe, A; Magro, D; Piccaluga, Pp; Fuligni, F; Paolini, S; Ricciardi, Teresa; Picardi, P; Giacomini, Elisa; Rocchi, MARCO BRUNO LUIGI; Magnani, Mauro; Visani, G. | |
| Prospective Study of EGFR Intron 1 CA tandem repeats as predict factor benefit from cetuximab and irinotecan | 1-gen-2012 | Antoniotti, C; Loupakis, F; Cremolini, C; Zhang, W; Yang, Dy; Wakatsuki, T; Schirripa, M; Salvatore, L; Ricci, V; Graziano, F; Masi, G; Ruzzo, Annamaria; Labonte, Mj; Ning, Y; El Khoueiry, R; Falcone, A; Lenz, Hj | |
| Pharmacogenetic profiling for toxicity of oxaliplatin and fluoripyrimidines. An Ancillary protocol to the TOSCA trial | 1-gen-2012 | Ruzzo, Annamaria; Galli, F; Floriani, I; Rulli, E; Zagonel, V; Lonardi, S; Ronzoni, M; Massidda, B; Pella, N; Mucciarini, C; Labianca, R; Ziranu, P; Veltri, E; Sozzi, P; Barni, S; Ricci, V; Foltran, L; Pasquini, E; Nuzzo, A; Bramati, A; Turci, D; Lazzarelli, S; Verusio, C; Bergamo, F; Giacomini, E; Sobrero, A; Frontini, L; Magnani, Mauro; Graziano, F. | |
| High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease | 1-gen-2012 | Ruzzo, Annamaria; Graziano, F; Vincenzi, B; Canestrari, E; Perrone, G; Galluccio, N; Catalano, V; Loupakis, F; Rabitti, C; Santini, D; Tonini, G; Fiorentini, G; Rossi, D; Falcone, A; Magnani, Mauro | |
| Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV) | 1-gen-2012 | Cremolini, C.; Loupakis, F.; Yang, Dy; Salvatore, L.; Zhang, W.; Wakatsuki, T.; Schirripa, M.; Lonardi, S.; Antoniotti, C.; Aprile, G.; Masi, G.; Graziano, F.; Ruzzo, Annamaria; Lucchesi, S.; Ronzoni, M.; Maus, Mkh; Bocci, G.; Tonini, G.; Falcone, A.; Lenz, Hj | |
| PROSPECTIVE EVALUATION OF CANDIDATE SNPS OF VEGF/VEGFR PATHWAY IN METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) | 1-gen-2012 | Cremolini, C; Loupakis, F; Yang, Dy; Salvatore, L; Zhang, W; Wakatsuky, T; Schirripa, M; Antoniotti, C; Aprile, G; Masi, G; Graziano, F; Ruzzo, A; Lucchesi, S; Maus, M; Bocci, G; Falcone, A; Lenz, Hj; Lonardi, S | |
| PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. | 1-gen-2012 | Vincenzi, B; Santini, D; Perrone, G; Graziano, F; Loupakis, F; Schiavon, G; Frezza, Am; Ruzzo, Annamaria; Rizzo, S; Crucitti, P; Galluzzo, S; Zoccoli, A; Rabitti, C; Muda, Ao; Russo, A; Falcone, A; Tonini, G. | |
| Let-7a microRNA levels in KRAS-mutated colorectal carcinomas determine survival differences in patients treated with anti-EGFR | 1-gen-2011 | Canestrari, E; Ruzzo, Annamaria; Vincenzi, B; Galluccio, N; Perrone, G; Andreoni, Francesca; Lorenzini, P; Rulli, E; D'Emidio, S; Catalano, V; Loupakis, F; Bisonni, R; Floriani, I; De Nictolis, M; Santini, D; Salvatore, L; Tonini, G; Falcone, A; Magnani, Mauro; Graziano, F. | |
| Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer | 1-gen-2011 | Loupakis, F; Ruzzo, Annamaria; Salvatore, L; Cremolini, C; Masi, G; Frumento, P; Schirripa, M; Catalano, V; Galluccio, N; Canestrari, E; Vincenzi, B; Santini, D; Bencardino, K; Ricci, V; Manzoni, M; Danova, M; Tonini, G; Magnani, Mauro; Falcone, A; Graziano, F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile